Pathomorphology of the atypical form of congenital hyperinsulinism on the example of three clinical cases

Background. Congenital hyperinsulinism (CH) is characterized by persistent hypoglycemia, leading to irreversible damage to the cerebral cortex. The atypical form of CH (ACH) remains practically unexplored. Objective. Description of histological and immunohistochemical features of the pancreas in ACH. Design and methods. Material for research — fragments of the resected pancreas of 3 children with ACH aged 3, 6 and 7 months. Control group — pancreas of 9 children who died from heart malformations. Pancreatic tissue was stained with hematoxylin and eosin, an immunohistochemical reaction was performed with antibodies to chromogranin A, somatostatin, and transcription factors (TF) NeuroD1, Nkx2.2, and Isl1. Results. In all patients, numerous hyperplastic islets of Langerhans were observed, which in places merged with each other. In two patients, the lesion was limited to the pancreas area, and in one it covered the entire gland. All patients showed a sharp increase (p < 0.01) in the expression of NeuroD1 both in the exocrine and endocrine parts of the pancreas in the affected area: in 79.0 ± 23.4 % of endocrinocytes and in 88.0 ± 8.2 % of exocrinocytes (in the control 10.5 ± 7.9 % and 4.0 ± 4.9 % respectively). The expression of chromogranin A and TF Isl1 and Nkx2.2 increased statistically significantly (p < 0.01) only in affected endocrinocytes (chromogranin A — 62.3 ± 15.4 % of endocrinocytes, Isl1 — 82.0 ± 4.6 %, Nkx2.2 — 81.3 ± 4.6 %; in the control — 39.4 ± 7.9 %, 30.2 ± 16.2 % and 26.4 ± 11.9 % respectively). In 2 patients, there was a tendency to an increase in the number of somatostatin + endocrinocytes. Conclusion. ACH is morphologically very heterogeneous. Like other forms of CH, ACH was characterized by a statistically significant increase in the expression of chromogranin A and TF NeuroD1, Nkx2.2, Isl1, while the expression of somatostatin in general remained unchanged.

atypical form of congenital hyperinsulinism, chromogranin A, congenital hyperinsulinism, hypertrophy of endocrinocyte nuclei, immunohistochemical study, Isl1, NeuroD1, Nkx2.2, somatostatin

1. Menni F, de Lonlay P, Sevin C, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001; 107 (3): 476–479.

2. Lord K, De León DD. Hyperinsulinism in the Neonate. Clin Perinatol. 2018; 45 (1): 61–74.

3. Stanley CA. Advances in diagnosis and treatment of hyperinsulinism in infants and children. J Clin Endocrinol Metab. 2002; 87 (11): 4857–4859.

4. Otonkoski T, Ammala C, Huopio H, et al. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes. 1999; 48 (2): 408–415.

5. Mathew PM, Young JM, Abu-Osba YK, et al. Persistent neonatal hyperinsulinism. Clin Pediatr (Phila). 1988; 27 (3): 148–151.

6. Galcheva S, Demirbilek H, Al-Khawaga S, et al. The genetic and molecular mechanisms of congenital hyperinsulinism. Front Endocrinol. 2019; 10: 111.

7. Sempoux Ch, Guiot Y, Jaubert F, et al. Focal and diffuse forms of congenital hyperinsulinism: the keys for differential diagnosis. Endocr Pathol. 2004; 15 (3): 241–246.

8. Han B, Mohamed Z, Estebanez MS, et al. Atypical forms of congenital hyperinsulinism in infancy are associated with mosaic patterns of immature islet cells. J Clin Endocrinol Metab. 2017; 102 (9): 3261–3267.

9. Houghton JA, Banerjee I, Shaikh G, et al. Unravelling the genetic causes of mosaic islet morphology in congenital hyperinsulinism. J Pathol Clin Res. 2020; 6 (1): 12–16.

10. Snider KE, Becker S, Boyajian L, et al. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013; 98 (2): E355–363.

11. Hussain K, Flanagan S E, Smith VV, et al. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes. 2008; 57 (1): 259–263.

12. Lord K, Dzata E, Snider KE, et al. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab. 2013; 98 (11): E1786–1789.

13. Ni J, Ge J, Zhang M, et al. Genotype and phenotype analysis of a cohort of patients with congenital hyperinsulinism based on DOPA-PET CT scanning. Eur J Pediatr. 2019; 178 (8): 1161–1169.

14. Pataskar A, Jung J, Smialowski P, et al. NeuroD1 reprograms chromatin and transcription factor landscapes to induce the neuronal program. EMBO J. 2016; 35 (1): 24–45.

15. Romer AI, Singer RA, Sui L, et al. Murine perinatal β-cell proliferation and the differentiation of human stem cell-derived insulin-expressing cells require NEUROD1. Diabetes. 2019; 68 (12): 2259–2271.

16. Habener JF, Kemp DM, Thomas MK. Minireview: transcriptional regulation in pancreatic development. Endocrinology. 2005; 146 (3): 1025–1034.

17. Anderson KR, Torres CA, Solomon K, et al. Cooperative transcriptional regulation of the essential pancreatic islet gene NeuroD1 (beta2) by Nkx2.2 and neurogenin 3. J Biol Chem. 2009; 284 (45): 31236–31248.

18. Krivova YS, Barabanov VM, Proshchina AE, et al. Distribution of chromogranin A in human fetal pancreas. Bull Exp Biol Med. 2013; 156 (12): 839–842. In Russian

19. Braun M. The somatostatin receptor in human pancreatic β-cells. Vitam Horm. 2014; 95: 165–193.

20. Mitrofanova LB, Hazratov AO, Galkovsky BE, et al. Immunohistochemical study of NeuroD1, Nkx2.2, Isl1 transcription factors, somatostatin and chromogranin a in different forms of congenital hyperinsulinism. Molecular medicine. 2020; 18 (1): 36–47. In Russian

21. Stanik J, Skopkova M, Brennerova K, et al. Congenital hyperinsulinism and glycogenosis-like phenotype due to a novel HNF4A mutation. Diabetes Res Clin Pract. 2017; 126: 144–150.